Suppr超能文献

糠酸莫米松的代谢物和降解产物具有显著的受体亲和力。

Significant receptor affinities of metabolites and a degradation product of mometasone furoate.

作者信息

Valotis Anagnostis, Högger Petra

机构信息

Institut für Pharmazie und Lebensmittelchemie, Bayerische Julius-Maximilians-Universität, Würzburg, Germany.

出版信息

Respir Res. 2004 Jul 22;5(1):7. doi: 10.1186/1465-9921-5-7.

Abstract

Mometasone furoate (MF) is a highly potent glucocorticoid used topically to treat inflammation in the lung, nose and on the skin. However, so far no information has been published on the human glucocorticoid receptor activity of the metabolites or degradation products of MF. We have now determined the relative receptor binding affinities of the known metabolite 6beta-OH MF and the degradation product 9,11-epoxy MF to understand their possible contribution to undesirable systemic side effects. In competition experiments with human lung glucocorticoid receptors we have determined the relative receptor affinities (RRA) of these substances with reference to dexamethasone (RRA = 100). We have discovered that 6beta-OH MF and 9,11-epoxy MF display RRAs of 206 +/- 15 and 220 +/- 22, respectively. This level of activity is similar to that of the clinically used inhaled corticosteroid flunisolide (RRA 180 +/- 11). Furthermore we observed that 9,11-epoxy MF is a chemically reactive metabolite. In recovery experiments with human plasma and lung tissue we found a time dependent decrease in extractability of the compound. Hence, we provide data that might contribute to the understanding of the pharmacokinetics as well as the clinical effects of MF.

摘要

糠酸莫米松(MF)是一种强效糖皮质激素,用于局部治疗肺部、鼻部和皮肤的炎症。然而,迄今为止,尚未有关于MF代谢产物或降解产物的人糖皮质激素受体活性的信息发表。我们现已确定了已知代谢产物6β-羟基MF和降解产物9,11-环氧MF的相对受体结合亲和力,以了解它们对不良全身副作用可能产生的影响。在与人肺糖皮质激素受体的竞争实验中,我们参照地塞米松(相对受体亲和力[RRA]=100)确定了这些物质的相对受体亲和力。我们发现,6β-羟基MF和9,11-环氧MF的RRA分别为206±15和220±22。这种活性水平与临床使用的吸入性糖皮质激素氟尼缩松(RRA 180±11)相似。此外,我们观察到9,11-环氧MF是一种化学反应性代谢产物。在用人血浆和肺组织进行的回收实验中,我们发现该化合物的可提取性随时间下降。因此,我们提供的数据可能有助于理解MF的药代动力学以及临床效果。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5c82/499542/86a59cadaea1/1465-9921-5-7-1.jpg

相似文献

3
Metabolism of mometasone furoate and biological activity of the metabolites.
Drug Metab Dispos. 2006 Feb;34(2):225-33. doi: 10.1124/dmd.105.005702. Epub 2005 Oct 26.
4
Human receptor kinetics, tissue binding affinity, and stability of mometasone furoate.
J Pharm Sci. 2004 May;93(5):1337-50. doi: 10.1002/jps.20049.
7
Mometasone furoate degradation and metabolism in human biological fluids and tissues.
Biopharm Drug Dispos. 2003 Nov;24(8):321-33. doi: 10.1002/bdd.362.
8
Induced-fit docking of mometasone furoate and further evidence for glucocorticoid receptor 17alpha pocket flexibility.
J Mol Graph Model. 2008 Nov;27(4):512-21. doi: 10.1016/j.jmgm.2008.09.002. Epub 2008 Sep 10.
9
Kinetics of metabolism and degradation of mometasone furoate in rat biological fluids and tissues.
J Pharm Pharmacol. 2003 May;55(5):617-30. doi: 10.1211/002235703765344522.

引用本文的文献

1
Mometasone Furoate Suppresses PMA-Induced MUC-5AC and MUC-2 Production in Human Airway Epithelial Cells.
Tuberc Respir Dis (Seoul). 2017 Jan;80(1):60-68. doi: 10.4046/trd.2017.80.1.60. Epub 2016 Dec 30.
2
Mometasone furoate in the management of asthma: a review.
Ther Clin Risk Manag. 2008 Dec;4(6):1201-8. doi: 10.2147/tcrm.s3261.

本文引用的文献

1
Human receptor kinetics, tissue binding affinity, and stability of mometasone furoate.
J Pharm Sci. 2004 May;93(5):1337-50. doi: 10.1002/jps.20049.
2
Corticosteroid allergy in asthma.
Allergy. 2003 Nov;58(11):1131-5. doi: 10.1046/j.1398-9995.2003.00297.x.
3
Mometasone furoate degradation and metabolism in human biological fluids and tissues.
Biopharm Drug Dispos. 2003 Nov;24(8):321-33. doi: 10.1002/bdd.362.
4
Kinetics of metabolism and degradation of mometasone furoate in rat biological fluids and tissues.
J Pharm Pharmacol. 2003 May;55(5):617-30. doi: 10.1211/002235703765344522.
5
Degradation kinetics of mometasone furoate in aqueous systems.
Int J Pharm. 2003 Jun 18;259(1-2):129-41. doi: 10.1016/s0378-5173(03)00226-6.
6
Intranasal corticosteroids for allergic rhinitis.
Pharmacotherapy. 2002 Nov;22(11):1458-67. doi: 10.1592/phco.22.16.1458.33692.
7
Bioavailability and metabolism of mometasone furoate: pharmacology versus methodology.
J Clin Pharmacol. 2002 Apr;42(4):383-7. doi: 10.1177/0091270002424003.
8
New and established topical corticosteroids in dermatology: clinical pharmacology and therapeutic use.
Am J Clin Dermatol. 2002;3(1):47-58. doi: 10.2165/00128071-200203010-00005.
9
Mometason furoate levels.
Chest. 2001 Sep;120(3):1034-5. doi: 10.1378/chest.120.3.1034.
10
Inhaled mometasone furoate: a review of its use in adults and adolescents with persistent asthma.
Drugs. 2001;61(9):1325-50. doi: 10.2165/00003495-200161090-00011.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验